

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Claesson Welsh et al. Art Unit : 1614
Serial No. : 10/563,389 Examiner : Unknown
Filed : January 5, 2006 Conf. No. : 2997
Title : AN ENDOGENOUS PEPTIDE AND ACTIVE SUBFRAGMENTS THEREOF

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Jan 24, 2007


Ronald C. Lundquist, Ph.D.
Reg. No. 37,875

Fish & Richardson P.C.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15665-007US1	Application No. 10/563,389
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Claesson Welsh et al.	
		Filing Date January 5, 2006	Group Art Unit 1614

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	US2001/041670	11/15/2001	Simantov, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AL	WO02/076486	10/03/2002	WIPO			
	AM	WO03/077872	09/25/2003	WIPO			
	AN	WO02/064621	08/22/2002	WIPO			
	AO						
	AP						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	J.C. Juarez, et al. "Histidine-proline-rich Glycoprotein has potent antiangiogenic activity mediated through the histidine-proline domain" <u>Cancer Research</u> Vol. 62 (September 15, 2002), pgs. 5344-5350
	AR	R. Simantov, et al. "Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1" <u>The Journal of Clinical Investigation</u> (January 2001) Vol. 107 (1), pgs. 45-52
	AS	A. Olsson, et al. "A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization" <u>Cancer Research</u> Vol. 64 (2004) pgs. 599-605

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15665-007US1	Application No. 10/563,389
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Claesson Welsh et al.	
		Filing Date January 5, 2006	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AT	Hulett M.D., et al. "Murine histidine-rich glycoprotein: Cloning, characterization and cellular origin" <u>Immunology and Cell Biology</u> (2000) 78, pgs. 280-287
	AU	D.J. Borza, et al. "Domain structure and conformation of histidine-roline-rich glycoprotein" <u>Biochemistry</u> (1996) Vol. 35, pgs. 1925-1934
	AV	T. Kolde, et al. "Amino Acid Sequence of Human Histidine-Rich Glycoprotein Derived from the Nucleotide Sequence of its cDNA" <u>Biochemistry</u> Vol. 25 (1986), pgs. 2220-2225
	AW	H.K. Lunen, et al. "Interaction of Heparin with Histidine-rich Glycoprotein" <u>Annals New York Academy of Sciences</u> Vol. 556 (1985), pgs. 181-185

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	